APOC3 and hypertriglyceridemia: Phase III studies (APPROACH and COMPASS) with participants with FCS or severe hypertriglyceridemia (TG > 500 mg/dL), showed 84% reduction in apoC-III and >70% reduction in TG levels after weekly administration of 300 mg Volanesorsen [15,70].